Gilead withdraws bladder cancer drug in US after failed trial
1 day ago · GILD. (Reuters) -Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of bladder cancer after it failed to meet the main goal in a ...
Gilead Sciences Voluntarily Pulls Drug for Bladder Cancer After …
1 day ago · By Frank Vinluan on October 18, 2024. Gilead Sciences is voluntarily withdrawing cancer drug Trodelvy from the U.S. market as a treatment for advanced cases of urothelial carcinoma, a move that ...
Gilead withdraws Trodelvy in bladder cancer after trial flop
1 day ago · Following the setback in that study, called EVOKE-01, Gilead recognized an impairment charge of $2.4 billion. Trodelvy was the crown jewel in Gilead’s $21 billion acquisition of Immunomedics in ...
Gilead withdraws Trodelvy in bladder cancer - Yahoo Finance
1 day ago · Gilead will no longer sell its combination drug Trodelvy to treat bladder cancer, announcing Friday it had agreed with the Food and Drug Administration to withdraw it following negative trial ...
Gilead to Withdraw U.S. Accelerated Approval for Trodelvy in …
1 day ago · Gilead reported worldwide Trodelvy sales of $628 million for the first six months of the year, representing less than 5% of the company's revenue of more than $13.6 billion for the period.
Gilead to pull Trodelvy U.S. indication on trial setback - MSN
10m. Gilead (NASDAQ: GILD) on Friday announced plans to voluntarily withdraw a U.S. indication for its antibody-drug conjugate Trodelvy in bladder cancer after a late-stage confirmatory trial for ...
Gilead's Trodelvy triplet underwhelms, but exec says data bolster ...
Sep 9, 2024 · Gilead Sciences has been looking for a win for Trodelvy after two surprise trial failures earlier this year. But it looks like that win won’t come from a triplet regimen that combines the...
Gilead Provides Update on Phase 3 TROPiCS-04 Study - Gilead Sciences
May 30, 2024 · The TROPiCS-04 study is an open-label, global, multi-center, randomized Phase 3 study that evaluated Trodelvy vs. single-agent chemotherapy (treatment of physicians’ choice, TPC) in patients with locally advanced or mUC who received platinum-containing chemotherapy and checkpoint inhibitor therapy.
U.S. FDA Grants Accelerated Approval to Trodelvy for the …
Apr 13, 2021 · The Phase 2 TROPHY-U01 (also known as IMMU-132-06) trial is an ongoing, international, multi-center, open-label, multi-cohort, single-arm study evaluating Trodelvy monotherapy or combination therapy in patients with metastatic UC after progression on a platinum-based regimen and anti-PD-1/PD-L1-based immunotherapy.
Gilead Withdraws ADC Trodelvy in Bladder Cancer After Trial Failure
1 day ago · The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for bladder cancer in 2021, failed its confirmatory trial earlier this year. Gilead is withdrawing Trodelvy from the market in bladder cancer after a confirmatory study did not meet its primary endpoint.